<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113551</url>
  </required_header>
  <id_info>
    <org_study_id>CR108692</org_study_id>
    <secondary_id>PCSESP001604</secondary_id>
    <nct_id>NCT04113551</nct_id>
  </id_info>
  <brief_title>A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan</brief_title>
  <official_title>Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan: A Retrospective Cohort Study of Label Compliance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to document the extent of on-label and off-label use of
      Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in
      Japan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">January 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Stratified on Age, Sex, and Medication</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>The percentage of participants stratified on age, sex, and medication (Methylphenidate [MPH] [Concerta], MPH [Ritalin], Atomoxetine [ATO], Guanfacine [GFC]) will be reported. The data will be taken from Japan Medical Data Center (JMDC) database for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of the Specialty of the Department of the First Prescriber who Prescribe MPH (Concerta), MPH (Ritalin), ATO, or GFC</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>The percentage of specialty of the department of the first prescriber for each first dispensing of each study medication will be reported. The data will be taken from JMDC database for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants whose First Prescription for MPH (Concerta), MPH (Ritalin), ATO, or GFC was Associated with an On-label Diagnosis</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>The percentage of participants whose first prescription for MPH (Concerta), MPH (Ritalin), ATO, or GFC was associated with an on-label diagnosis, that is, a diagnosis of Attention Deficit Disorder with Hyperactivity (ADHD) for MPH (Concerta), ATO or GFC; or a diagnosis of narcolepsy for MPH (Ritalin) will be reported. The data will be taken from JMDC database for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Received More than Maximum Recommended Dose of MPH (Concerta), MPH (Ritalin), Methylphenidate (Concerta and Ritalin), ATO, or GFC</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>The percentage of participants who received more than the maximum recommended dose of MPH (Concerta), MPH (Ritalin), Methylphenidate (Concerta and Ritalin), ATO, or GFC will be reported. The data will be taken from JMDC database for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants not Meeting Age Criteria at the Time of Receiving Medication</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>Percentage of participants who at the time of receiving the medication were outside the approved age range will be reported. The data will be taken from JMDC database for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants not Meeting Medication Criteria at the Time of Receiving Medication</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>Percentage of participants who at the time of receiving the medication had other contraindications will be reported. The data will be taken from JMDC database for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants whose Prescriptions were Consistent with all Aspects of the Label that was Current at the Time of the Prescription</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>Percentage of participants whose prescriptions were consistent with all aspects of the label that was current at the time of the prescription will be reported. The data will be taken from JMDC database for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Shopping Behavior as a Marker of Misuse of Medications</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>Percentage of participants whose use pattern of MPH (Concerta), MPH (Ritalin), MPH (Concerta and Ritalin) or ATO included prescriptions from three or more departments within any 18-month period will be reported. This describes &quot;shopping behavior&quot;, which is a marker for misuse or abuse of medications. The data will be taken from JMDC database for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Trends in Percentage of Participants Compliant with all Label Requirements</measure>
    <time_frame>Up to 5.8 years</time_frame>
    <description>The time trends in the percentage of participants whose prescriptions complied with all requirements of the label for MPH (Concerta), MPH (Ritalin), MPH (Concerta and Ritalin), ATO, and GFC will be reported. The data will be taken from JMDC database for analysis.</description>
  </primary_outcome>
  <number_of_groups>14</number_of_groups>
  <enrollment type="Actual">17418</enrollment>
  <condition>Attention Deficit Disorder With Hyperactivity</condition>
  <arm_group>
    <arm_group_label>Cohort T1: Methylphenidate (MPH) (Concerta)</arm_group_label>
    <description>Analysis of data will be performed for participants who have had first exposure of MPH (Concerta) and who were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T2: MPH (Ritalin)</arm_group_label>
    <description>Analysis of data will be performed for participants who have had first exposure of MPH (Ritalin) and who were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T3: MPH (Concerta and Ritalin)</arm_group_label>
    <description>Analysis of data will be performed for participants who have had exposure to Concerta and Ritalin during the time in the cohort between 1 January 2013 and 30 September 2018 and has continuous observation of at least 30 days prior to the exposures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T4: Atomoxetine (ATO)</arm_group_label>
    <description>Analysis of data will be performed for participants who have had first exposure of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T5: Guanfacine (GFC)</arm_group_label>
    <description>Analysis of data will be performed for participants who have had first exposure of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC</arm_group_label>
    <description>Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin), ATO, or GFC first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T7: MPH (Concerta or Ritalin)</arm_group_label>
    <description>Analysis of data will be performed for participants who had have MPH (Concerta or Ritalin) first exposure between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior. These are the first exposure to any MPH among the participants with who had some exposure to MPH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T8: MPH (Concerta) All Exposures</arm_group_label>
    <description>Analysis of data will be performed for participants who have had all exposures of MPH (Concerta) and were never exposed to MPH (Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T9: MPH (Ritalin) All Exposures</arm_group_label>
    <description>Analysis of data will be performed for participants who have had all exposures of MPH (Ritalin) and were never exposed to MPH (Concerta) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T10: ATO All Exposures</arm_group_label>
    <description>Analysis of data will be performed for participants who have had all exposures of ATO between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T11: GFC All Exposures</arm_group_label>
    <description>Analysis of data will be performed for participants who have had all exposures of GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures</arm_group_label>
    <description>Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin), ATO, or GFC between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any study drug(s) among the participants with an exposure to at least one of the study drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T13: MPH (Concerta or Ritalin) All Exposures</arm_group_label>
    <description>Analysis of data will be performed for participants who have had all exposures of MPH (Concerta or Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta or Ritalin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort T14: MPH (Concerta and Ritalin) All Exposures</arm_group_label>
    <description>Analysis of data will be performed for participants who have had all exposures of MPH (Concerta and Ritalin) between 1 January 2013 and 30 September 2018 that also has continuous observation of at least 30 days prior to exposure. These are all exposures to any MPH (Concerta or Ritalin) among the participants with an exposure to MPH (Concerta) during the study period and to an exposure to MPH (Ritalin) during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPH (Concerta)</intervention_name>
    <description>MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.</description>
    <arm_group_label>Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures</arm_group_label>
    <arm_group_label>Cohort T13: MPH (Concerta or Ritalin) All Exposures</arm_group_label>
    <arm_group_label>Cohort T14: MPH (Concerta and Ritalin) All Exposures</arm_group_label>
    <arm_group_label>Cohort T1: Methylphenidate (MPH) (Concerta)</arm_group_label>
    <arm_group_label>Cohort T3: MPH (Concerta and Ritalin)</arm_group_label>
    <arm_group_label>Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC</arm_group_label>
    <arm_group_label>Cohort T7: MPH (Concerta or Ritalin)</arm_group_label>
    <arm_group_label>Cohort T8: MPH (Concerta) All Exposures</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPH (Ritalin)</intervention_name>
    <description>MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.</description>
    <arm_group_label>Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures</arm_group_label>
    <arm_group_label>Cohort T13: MPH (Concerta or Ritalin) All Exposures</arm_group_label>
    <arm_group_label>Cohort T14: MPH (Concerta and Ritalin) All Exposures</arm_group_label>
    <arm_group_label>Cohort T2: MPH (Ritalin)</arm_group_label>
    <arm_group_label>Cohort T3: MPH (Concerta and Ritalin)</arm_group_label>
    <arm_group_label>Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC</arm_group_label>
    <arm_group_label>Cohort T7: MPH (Concerta or Ritalin)</arm_group_label>
    <arm_group_label>Cohort T9: MPH (Ritalin) All Exposures</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine (ATO)</intervention_name>
    <description>Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.</description>
    <arm_group_label>Cohort T10: ATO All Exposures</arm_group_label>
    <arm_group_label>Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures</arm_group_label>
    <arm_group_label>Cohort T4: Atomoxetine (ATO)</arm_group_label>
    <arm_group_label>Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine (GFC)</intervention_name>
    <description>Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.</description>
    <arm_group_label>Cohort T11: GFC All Exposures</arm_group_label>
    <arm_group_label>Cohort T12:MPH(Concerta and Ritalin),ATO,orGFC All Exposures</arm_group_label>
    <arm_group_label>Cohort T5: Guanfacine (GFC)</arm_group_label>
    <arm_group_label>Cohort T6: MPH (Concerta and Ritalin), ATO, or GFC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will comprise of population (participants with attention
        deficit/hyperactivity disorder [ADHD]) described in the Japan Medical Data Center (JMDC)
        database which has data available through 1 January 2005 to 30 September 2018.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants have been in the database for greater than or equal to (&gt;=) 30 days

          -  Have received, between 1 January, 2013 and 30 September, 2018, a prescription for
             Concerta, Ritalin, Atomoxetine (ATO) or Guanfacine (GFC)

        Exclusion Criteria:

        - Participants who received an unspecified Methylphenidate (MPH) formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research and Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research and Development LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Janssen Investigative Site</name>
      <address>
        <city>Titusville</city>
        <state>New Jersey</state>
        <zip>08560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanfacine</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

